Daiichi Sankyo, Sanofi Heart Drug Shows No Superiority Over Plavix
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo said a comparative Phase III trial of its Effient (prasugrel) antiplatelet drug against Sanofi's Plavix (clopidogrel) showed no improvement in treating unstable angina and myocardial infarction.